New cell therapy takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-phase study tests a new treatment called BOXR1030, which uses specially designed immune cells to target a protein (GPC3) found on certain advanced solid tumors. The study involves 7 adults with liver, lung, skin, or soft tissue cancers that have not responded to standa…
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated May 17, 2026 04:33 UTC